Anavex life sciences to present at the h.c. wainwright global life sciences conference

New york, march 04, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will present at the h.c. wainwright global life sciences conference being held from march 9-10, 2021.
AVXL Ratings Summary
AVXL Quant Ranking